Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Silence Therapeutics has signed a deal with Mirna Therapeutics to evaluate the delivery capabilities of Silence's AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs, targeting cancer.
Subscribe to our email newsletter
Under the terms of thecollaboration, Mirna will provide Silence with specific miRNA sequences, to formulate with AtuPLEX and DBTC delivery systems and develop multiple candidate drugs.
Mirna, on the other hand, will conduct in vitro and in vivo studies of the candidate drugs developed under the deal and choose lead candidates for further assessment.
Silence Therapeutics CEO Thomas Christely said the second collaboration with Mirna will explore the use of Silence’s delivery technologies to deliver microRNAs.
"With our delivery systems AtuPLEX, DACC and DBTC, Silence has an increasing range of delivery options to help overcome these challenges," Christely added.
The financial terms of the deal, however, have not been disclosed.